Corticosteroid therapy for severe COVID-19 pneumonia: optimal dose and duration of administration

  • Matsuda W
  • Okamoto T
  • Uemura T
  • et al.
N/ACitations
Citations of this article
42Readers
Mendeley users who have this article in their library.

Abstract

Severe COVID-19 is associated with a hyperinflammatory state, and corticosteroid therapy may be effective. We review the recent literature and discuss the appropriate dose and duration of corticosteroid therapy. Low-dose corticosteroid therapy is often used to treat COVID-19. However, several doses of methylprednisolone (or prednisolone) have been attempted, ranging from about 40 mg/day to 2 mg/kg/day. Doses may need to be adjusted depending on severity. Corticosteroid therapy is generally administered for a short period over several days. However, COVID-19-induced respiratory failure is often prolonged, so longer administration may be considered. Careful monitoring for complications due to corticosteroid therapy is vital.

Cite

CITATION STYLE

APA

Matsuda, W., Okamoto, T., Uemura, T., Kobayashi, K., Sasaki, R., & Kimura, A. (2020). Corticosteroid therapy for severe COVID-19 pneumonia: optimal dose and duration of administration. Global Health & Medicine, 2(3), 193–196. https://doi.org/10.35772/ghm.2020.01046

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free